{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:44:28Z","timestamp":1793187868358,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>High-grade astrocytoma with piloid features (HGAP) is a recently described primary brain tumor and the first requiring a specific methylation pattern for diagnosis, as its histologic features are often compatible with other tumors such as glioblastoma (GBM). Characterized by molecular alterations in <jats:italic>CDKN2A\/B<\/jats:italic>,<jats:italic> NF1<\/jats:italic>,<jats:italic> BRAF<\/jats:italic>,<jats:italic> FGFR1<\/jats:italic>, and <jats:italic>ATRX<\/jats:italic>, they may be located anywhere in the CNS but show a predilection for the posterior fossa. Reports are limited to retrospective case series, and the standard of care is not yet established. We performed a retrospective review of electronic medical records of all patients with HGAP at our institution. Records were queried for demographic, radiographic, clinical, surgical, pathologic, and outcome data. Eighteen patients were included with a median 17.1 months follow-up. Of these, 12 (63.2%) were women with a mean age of 43 years (range 24\u201367). The most common tumor locations were the cerebellum (8 patients, 42.1%) and thalamus (6 patients, 31.6%). On imaging, tumors were most commonly homogeneously contrast-enhancing (10 patients, 52.6%) or rim enhancing with central necrosis (5 patients, 26.3%). Ten patients (52.6%) underwent biopsy, while nine (47.4%) underwent resection, of which four (44.4%) underwent gross total resection. Adjuvant therapy included radiation in 16 patients (88.9%) and systemic treatment in 16 patients (88.9%). The initial systemic treatment was temozolomide in 14 patients (77.8%). One patient received upfront trametinib (a MEK1 inhibitor), and one patient received upfront dabrafenib (a BRAF inhibitor). At last follow up, 11 patients (57.9%) had progressive disease. Median progression-free survival (PFS) was 5.4 months (range 1.6\u201328.2 months), and median overall survival (OS) had not been reached. HGAP is a newly described rare glial tumor without an established standard of care. Its aggressive behavior and targetable mutations warrant further investigation regarding predictors of outcome for this entity.<\/jats:p>","DOI":"10.1186\/s40478-025-01987-0","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T01:54:45Z","timestamp":1745459685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["High-grade astrocytoma with piloid features: a single-institution case series and literature review"],"prefix":"10.1186","volume":"13","author":[{"given":"Eric A.","family":"Goethe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhiksha","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaminathan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujit S.","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Gubbiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherise D.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"22","key":"1987_CR1","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/diagnostics13223464","volume":"13","author":"M Alturkustani","year":"2023","unstructured":"Alturkustani M (2023) Diagnostic insights into pediatric pleomorphic Xanthoastrocytoma through DNA methylation class and pathological diagnosis analysis. Diagnostics (Basel) 13(22):3464. https:\/\/doi.org\/10.3390\/diagnostics13223464","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"1987_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11060-021-03749-z","volume":"153","author":"K Bender","year":"2021","unstructured":"Bender K, Perez E, Chirica M, Onken J, Kahn J, Brenner W et al (2021) High-grade Astrocytoma with piloid features (HGAP): the Charit\u00e9 experience with a new central nervous system tumor entity. J Neurooncol 153(1):109\u2013120. https:\/\/doi.org\/10.1007\/s11060-021-03749-z","journal-title":"J Neurooncol"},{"issue":"1","key":"1987_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40478-021-01222-6","volume":"9","author":"A Biczok","year":"2021","unstructured":"Biczok A, Str\u00fcbing FL, Eder JM, Egensperger R, Schnell O, Zausinger S et al (2021) Molecular diagnostics helps to identify distinct subgroups of spinal Astrocytomas. Acta Neuropathol Commun 9(1):119. https:\/\/doi.org\/10.1186\/s40478-021-01222-6","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"1987_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00401-022-02513-5","volume":"145","author":"PJ Cimino","year":"2023","unstructured":"Cimino PJ, Ketchum C, Turakulov R, Singh O, Abdullaev Z, Giannini C et al (2023) Expanded analysis of high-grade Astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1. Acta Neuropathol 145(1):71\u201382. https:\/\/doi.org\/10.1007\/s00401-022-02513-5","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1987_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/neuonc\/noac205","volume":"25","author":"SP Fortin Ensign","year":"2023","unstructured":"Fortin Ensign SP, Jenkins RB, Giannini C, Sarkaria JN, Galanis E, Kizilbash SH (2023) Translational significance of CDKN2A\/B homozygous deletion in isocitrate dehydrogenase-mutant Astrocytoma. Neuro Oncol 25(1):28\u201336. https:\/\/doi.org\/10.1093\/neuonc\/noac205","journal-title":"Neuro Oncol"},{"issue":"8","key":"1987_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"issue":"4","key":"1987_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00401-022-02478-5","volume":"144","author":"CHG Lucas","year":"2022","unstructured":"Lucas CHG, Sloan EA, Gupta R, Wu J, Pratt D, Vasudevan HN et al (2022) Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathol 144(4):747\u2013765. https:\/\/doi.org\/10.1007\/s00401-022-02478-5","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1987_CR8","doi-asserted-by":"publisher","first-page":"vdaa126","DOI":"10.1093\/noajnl\/vdaa126","volume":"2","author":"S Ma","year":"2020","unstructured":"Ma S, Rudra S, Campian JL, Dahiya S, Dunn GP, Johanns T et al (2020) Prognostic impact of CDKN2A\/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neurooncol Adv 2(1):vdaa126. https:\/\/doi.org\/10.1093\/noajnl\/vdaa126","journal-title":"Neurooncol Adv"},{"key":"1987_CR9","doi-asserted-by":"publisher","unstructured":"Qin T, Mullan B, Ravindran R, Messinger D, Saida R, Cummings JR et al (2022) ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. Cell Rep 38(2). https:\/\/doi.org\/10.1016\/j.celrep.2021.110216","DOI":"10.1016\/j.celrep.2021.110216"},{"issue":"1","key":"1987_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40478-019-0801-8","volume":"7","author":"A Reinhardt","year":"2019","unstructured":"Reinhardt A, Stichel D, Schrimpf D, Koelsche C, Wefers AK, Ebrahimi A et al (2019) Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathol Commun 7(1):163. https:\/\/doi.org\/10.1186\/s40478-019-0801-8","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"1987_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00401-018-1837-8","volume":"136","author":"A Reinhardt","year":"2018","unstructured":"Reinhardt A, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss DE et al (2018) Anaplastic Astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A\/B and ATRX alterations. Acta Neuropathol 136(2):273\u2013291. https:\/\/doi.org\/10.1007\/s00401-018-1837-8","journal-title":"Acta Neuropathol"},{"issue":"8","key":"1987_CR12","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/neuonc\/noad033","volume":"25","author":"CG Romo","year":"2023","unstructured":"Romo CG, Piotrowski AF, Campian JL, Diarte J, Rodriguez FJ, Bale TA et al (2023) Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1. Neuro Oncol 25(8):1474\u20131486. https:\/\/doi.org\/10.1093\/neuonc\/noad033","journal-title":"Neuro Oncol"},{"issue":"1","key":"1987_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.47391\/JPMA.24-05","volume":"74","author":"A Sohail","year":"2024","unstructured":"Sohail A, Virani QUA, Aziz HF, Shamim MS (2024) Prognostic value of BRAF mutation in glioblastoma. J Pak Med Assoc 74(1):185\u2013186. https:\/\/doi.org\/10.47391\/JPMA.24-05","journal-title":"J Pak Med Assoc"},{"issue":"4","key":"1987_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3174\/ajnr.A8166","volume":"45","author":"N Soni","year":"2024","unstructured":"Soni N, Agarwal A, Ajmera P, Mehta P, Gupta V, Vibhute M et al (2024) High-Grade Astrocytoma with piloid features: A dual institutional review of imaging findings of a novel entity. AJNR Am J Neuroradiol 45(4):468\u2013474. https:\/\/doi.org\/10.3174\/ajnr.A8166","journal-title":"AJNR Am J Neuroradiol"},{"issue":"21","key":"1987_CR15","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.3390\/cancers14215377","volume":"14","author":"K Szklener","year":"2022","unstructured":"Szklener K, Mazurek M, Wieteska M, Wac\u0142awska M, Bilski M, Ma\u0144dziuk S (2022) New directions in the therapy of glioblastoma. Cancers (Basel) 14(21):5377. https:\/\/doi.org\/10.3390\/cancers14215377","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1987_CR16","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.3390\/cimb45070335","volume":"45","author":"A Yuile","year":"2023","unstructured":"Yuile A, Satgunaseelan L, Wei JQ, Rodriguez M, Back M, Pavlakis N et al (2023) CDKN2A\/B homozygous deletions in astrocytomas: A literature review. Curr Issues Mol Biol 45(7):5276\u20135292. https:\/\/doi.org\/10.3390\/cimb45070335","journal-title":"Curr Issues Mol Biol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-01987-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-01987-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-01987-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T01:54:45Z","timestamp":1745459685000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-01987-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1987"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-01987-0","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University of Texas MD Anderson Cancer Center Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}